Material Modification to Rights of Security Holders

SEC Filing Summary: Healthcare Trust, Inc. (8-K)

Business Context and Reporting Period

This Current Report on Form 8-K was filed by Healthcare Trust, Inc. on December 8, 2020. The filing addresses a material modification to the rights of security holders regarding the company's poison pill defense mechanism. Note: While the request metadata mentions "National Healthcare Properties, Inc.", the filing text explicitly identifies the registrant as "Healthcare Trust, Inc."

Key Financial Metrics

This filing does not contain financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity metrics. The document is strictly a legal notice regarding corporate governance and shareholder rights.

Material Changes

  • Dividend Declaration: The Board of Directors declared a dividend of one common share purchase right (a "Right") for each share of common stock outstanding.
  • Record and Payable Dates: The dividend is payable on December 18, 2020, to stockholders of record on that date.
  • Exercise Terms: If the Rights become exercisable, each Right entitles the holder to purchase one share of common stock at a price of $31.50 per share, subject to adjustment.
  • Governing Agreement: The Rights are governed by a rights agreement dated May 18, 2020, with Computershare Trust Company, N.A., as rights agent.

Guidance, Outlook, and Risks

The filing does not provide financial guidance, management commentary on operations, or specific risk factors beyond the standard terms of the rights agreement. The primary purpose is to notify shareholders of the activation of the previously disclosed poison pill provision.

Key Facts for Investor Verification

  • Verify the exact number of common shares outstanding as of the December 18, 2020 record date to determine the total number of Rights issued.
  • Confirm the current status of the Rights (whether they have become exercisable or remain in a dormant state).
  • Review the May 19, 2020 Form 8-K referenced in this filing for the full text of the rights agreement and specific trigger events for exercisability.
  • Monitor for any subsequent filings regarding the adjustment of the $31.50 exercise price.
Disclaimer:
This AI-generated summary by MetaQuotes is based on SEC filings and may contain errors. Verify important details against the original SEC filings.